This website uses cookies to ensure you get the best experience on our website.
Privacy Statement

ABOUT US

HCMED INNOVATIONS PROVIDES A COMPREHENSIVE DRUG-DEVICE COMBINATION PLATFORM BUILT ON ITS CORE PRODUCT PORTFOLIO OF VIBRATING MESH NEBULIZERS

Mission

Our mission is to create highly integrated drug-device combination products for affordable-best-quality, featuring nebulization of high value therapeutic drugs that include small molecule synthetics and large molecule biologics, as either solutions, suspensions, and even difficult-to-deliver high viscosity drugs.

In order to achieve optimal aerosol performance for diverse formulations, we closely work with our partners to tailor the components and parameters of our mesh technology.

By combining the strength of Taiwan's world-class manufacturing industry and a well-established GMP certified manufacturing facility, our products have received approval by multiple health authorities and have been launched in selected regions.
 

Vision

We bring significant value to global pharma partners through a cost efficient and risk minimized pathway, designing combination products that can provide great contributions in the respiratory field.

Company History

Board of Directors

Strategic Advisors

  • Combination Development
    Pravin Soni, Ph.D.

    Pravin Soni is a consultant with over 30 years of experience. He has experience with successful FDA interactions relating to CMC aspects of drug, device, and combination medical products development, from early stage development through commercial launch. He was Vice President of Development at Alexza Pharmaceuticals where he led the development of the novel Staccato inhalation drug delivery platform. He served as a senior VP and CTO at Elevation Pharmaceuticals, where he was responsible for the development of a combination product using nebulized glycopyrrolate for the inhalation treatment of COPD that was successfully acquired by Sunovion pharmaceuticals for $430 million in 2012. He was co-founder of Patara Pharma where he was responsible for Development, Manufacturing, Quality and IP. Patara was acquired by Roivant Sciences and spun-off as Respivant Sciences, a Roivant Division. As Exec. VP of Respivant Sciences he was responsible for IP, Quality Assurance, Development, CMC-regulatory, Manufacturing and scale-up of a drug-device combination product for the treatment of refractory cough in Idiopathic Pulmonary Fibrosis (IPF). As current President of PharmaCRO, he provides consulting services that integrate product design, manufacturing, regulatory, quality, clinical, toxicology, and marketing requirements to identify the most efficient route to commercialization of safe, efficacious and reliable drug, device and combination medical products. Pravin has a Ph.D. in Polymer Science and Engineering from Case Western Reserve University. He has been granted sixty-three (63) patents.

  • Business Strategy
    Vera Wu, MBA

    Vera Wu is a Partner in KyrMar Advisory Services focused on providing local and multinational biotech and pharmaceutical companies support in their go-to-market and market expansion strategies and business development support in Taiwan. Vera led the business development efforts for EirGenix’s global trastuzumab licensing and supply deal with Sandoz Pharmaceuticals. Ms. Wu relocated from New York City where she last worked as a senior leader at Pfizer for over ten years. While there, Ms. Wu held various commercial roles including US LOE Asset Lead with responsibility for $3.0B USD in sales. Ms. Wu was a founding member of Pfizer’s Biosimiliar team responsible for gaining approval and launching ELELYSO globally. As a member of the Pfizer Corporate Strategy and Innovation team, Ms. Wu advised Pfizer’s CEO and executive leadership team on strategic options for complex corporate level opportunities. Before joining Pfizer, Ms. Wu worked as a principal consultant in Business Consulting Services for IBM (formerly PriceWaterhouseCoopers). Ms. Wu received her Master of Business Administration (MBA) in Finance and Strategic Management at The Wharton School, University of Pennsylvania in Philadelphia, Pennsylvania, and a Bachelor of Electrical Engineering from the University of Delaware.

  • Business Strategy
    Scott Fleming

    F. Scott Fleming is an accomplished pharmaceutical, drug delivery, and digital health executive with 28 years of experience developing, bringing to market, and monetizing new therapeutics. He has vast experience in the inhalation therapy industry and co-founded specialty pharmaceutical and drug delivery systems company MicroDose Therapeutx, which developed leading edge digital inhalers and respiratory diseases therapies. At MicroDose he negotiated numerous license agreements and joint ventures with major pharma and biotech partners, and in July 2013 sold the company to Teva Pharmaceuticals under a deal worth $165 million. He thereafter joined Teva’s Global Commercial Respiratory group and was global brand director for eConnectivity in Teva’s respiratory franchise for over 3 years. His career encompasses business development and strategy, contract negotiations, sales & marketing, brand development, fundraising, and multiple Director’s positions. He is an inventor on over one dozen patents and has been published in multiple peer reviewed journals. He resides in Amsterdam, the Netherlands.

  • Co-founder/Medical Advisor
    Shaogi Huang, M.D.

    Co-founder of HCmed Innovations Co., Ltd. Dr. Huang is an experienced pediatrician with extensive knowledge and training on the treatment of allergic and respiratory diseases, such as asthma, in children and infants. In 2014, he cofounded HCmed Innovations alongside Jason Cheng and Leon Tsai. Dr. Huang is currently a well-respected attending physician at Chang Gung Children's Hospital. He also serves as an active member of the Medical Education Committee of Chang Gung Hospital and the Children's Allergy and Asthma Society of the Republic of China.

Global operations

HCmed’s headquarters is located in Taipei City. Currently, our company counts with a GMP certified manufacturing site in Zhonghe, New Taipei City, while a second site is under construction in Wuxi, China.

Companies and institutions based in the US, Japan, China, and Taiwan are among our main local and foreign investors. HCmed Innovations is constantly expanding its parnerships worldwide, aiming to deliver top-quality inhalation treatment to people around the world.

  • Functional Sites
  • Investors
  • Partners
Wuxi, China: GMP Manufacturing Site
Taipei City: Headquarters and R&D Center
New Taipei City: GMP Manufacturing Site

1:Wuxi, China: GMP Manufacturing Site

2-1:Taipei City: Headquarters and R&D Center

2-2:New Taipei City: GMP Manufacturing Site

1:VIVO Capital

2:DCI Partners

3:H&Q Asia Pacific

4:Cathay Life Insurance | Mega Bank

1:Abbott, Brazil

2:China AstraZeneca, I-Campus Partner

3:SinoMedCare Biotech, China